.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Neurocrine Biosciences is reportedly finalizing the Neurocrine Soleno acquisition for over $2.5 billion. This strategic move aims to secure Soleno's lead candidate, Vykat XR, which addresses Prader-Willi syndrome. Furthermore, the potential transaction could value Soleno shares in the low-to-mid $50s range. Consequently, this deal highlights the growing value of specialized treatments for rare genetic conditions. Analysts expect an official announcement as early as Monday morning.
The Neurocrine Soleno acquisition provides Neurocrine with access to Vykat XR, a drug specifically designed for Prader-Willi syndrome. This condition causes constant hunger and significant developmental issues in patients. Therefore, clinicians anticipate that this acquisition will accelerate the global availability of the treatment. Additionally, Soleno recently went public in April 2024, showing rapid progress in its clinical pipeline. The company currently holds a market capitalization of approximately $2.04 billion.
Prader-Willi syndrome remains a challenging genetic disorder characterized by hyperphagia. Patients often struggle with obesity and metabolic complications due to an insatiable appetite. However, Vykat XR offers a promising therapeutic path for managing these complex symptoms. Specifically, the drug targets the physiological pathways responsible for appetite regulation and metabolic balance. Moreover, Neurocrine already manages Ingrezza for Huntington's disease, demonstrating their established expertise in complex brain and genetic disorders. This expertise will likely support the successful commercialization of Soleno's pipeline.
Q1: What is the primary drug involved in this acquisition?
The deal focuses on Vykat XR, a specialized treatment for Prader-Willi syndrome developed by Soleno Therapeutics to manage hyperphagia.
Q2: Why is Neurocrine interested in Soleno Therapeutics?
Neurocrine seeks to expand its portfolio in rare genetic and neurological disorders, complementing its existing products like Ingrezza for Huntington's disease.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Neurocrine Biosciences nears a $2.5 billion deal to acquire Soleno Therapeutics, adding a late-stage Prader-Willi syndrome drug to its rare disease portfoli...
5 months ago
A recent study highlights the utility of two-dimensional speckle tracking echocardiography in assessing right atrial mechanics in OSAHS. Progressive reductions in reservoir and conduit strain, coupled with elevated contraction strain, signal early right heart remodeling correlated with apnea severity.
Today
A multicentre RCT in China shows that the PAICS AI system significantly boosts sonographer sensitivity in detecting fetal intracranial malformations by 8.7% without compromising specificity, offering promising diagnostic support for prenatal neurosonography.
Today
A 2026 meta-analysis evaluates PDE5 inhibitors in advanced ILD with severe gas exchange impairment. While overall mortality was not significantly reduced, a targeted subgroup with pulmonary hypertension showed a 49% risk reduction, underscoring the necessity of precise hemodynamic phenotyping.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
The Supreme Court questioned FSSAI's phased warning approach, urging single-phase implementation for foods exceeding limits in any nutrient of concern. Backed by ICMR-NIN recommendations, the proposed red hexagonal warnings target added sugar, salt, and fat to combat India's escalating chronic disease epidemic.
Today
